The American Society of Hematology (ASH) has released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. The new guidelines recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors and aspirin therapy in select patients.